The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo.
 
Irene L.M. Reijers
Patents, Royalties, Other Intellectual Property - Drs. Reijers reports financial interest in Signature Oncology, and will receive some possible revenues if the IFN-y signature is being developed as clinical companion diagnostic.
 
Alexander M. Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; QBiotics; Roche
 
Judith M. Versluis
No Relationships to Disclose
 
Robyn P.M. Saw
Honoraria - BMS GmbH & Co. KG; Merck Sharp & Dohme; Novartis; Qbiotics
Consulting or Advisory Role - MSD; Qbiotics
Speakers' Bureau - Bristol-Myers Squibb/Sanofi; Novartis
Research Funding - Qbiotics
 
Winan J. van Houdt
Consulting or Advisory Role - Amgen (Inst); belpharma (Inst); Sanofi/Aventis (Inst)
Speakers' Bureau - Boehringer Ingelheim (Inst); MSD (Inst); Novartis (Inst)
 
Ellen Kapiteijn
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Delcath Systems (Inst); Ipsen (Inst); Lilly (Inst); Novartis (Inst); Pierre Fabre (Inst)
Research Funding - BMS (Inst); Pierre Fabre (Inst)
 
Astrid Aplonia Maria Van Der Veldt
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Merck (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst)
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - Bayer; MSD Oncology; Novartis; Roche; Roche
 
Karijn Suijkerbuijk
Consulting or Advisory Role - Abbvie (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Pierre Fabre (Inst)
Speakers' Bureau - Novartis (Inst); Roche (Inst)
Research Funding - Bristol Myers Squibb Foundation (Inst); Philips Research (Inst); TigaTx (Inst)
 
Hanna Eriksson
Honoraria - BMS (Inst); Novartis/Pfizer (Inst); Pierre Fabre (Inst)
Consulting or Advisory Role - BMS (Inst); MSD (Inst); Pierre Fabre (Inst)
Research Funding - Skyline Diagnostics (Inst)
 
Geke Hospers
Consulting or Advisory Role - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Seerave Foundation (Inst)
 
Willem M.C. Klop
No Relationships to Disclose
 
Marta I. Lopez-Yurda
No Relationships to Disclose
 
Lindsay G. Grijpink-Ongering
No Relationships to Disclose
 
Maria Gonzalez
No Relationships to Disclose
 
Andrew John Spillane
Honoraria - Lilly
 
Richard A. Scolyer
Employment - Royal Prince Alfred Hospital
Honoraria - GlaxoSmithKline; Harvard Medical School; Wake Forest School of Medicine
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb GesmbH (Austria); Bristol-Myers Squibb SA (Switzerland); Evaxion Biotech; GlaxoSmithKline; Merck Sharp & Dohme; metaoptima; MSD Sharp & Dohme (Australia) Pty Limited; Myriad Genetics; NeraCare GmbH; Novartis; Novartis; Novartis; Novartis; Provectus Biopharmaceuticals; QBiotics; Roche
Research Funding - Melanoma Research Alliance (MRA); National Health and Medical Research Council; National Health and Medical Research Council; National Health and Medical Research Council; The Ainsworth Foundation (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
(OPTIONAL) Uncompensated Relationships - Melanoma Institute Australia
 
Bart A. van de Wiel
Employment - BMSi
 
Alexander Christopher Jonathan Van Akkooi
Consulting or Advisory Role - 4SC (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Merck/Pfizer (Inst); MSD Oncology (Inst); Novartis (Inst); Pierre Fabre (Inst); Provectus Biopharmaceuticals; Sanofi (Inst); Sirius Medical (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck/Pfizer (Inst)
Travel, Accommodations, Expenses - Novartis
 
Georgina V. Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Evaxion Biotech; Hexal; Highlight Therapeutics; Innovent Biologics; Merck Sharp & Dohme; Novartis; OncoSec; PHMR; Pierre Fabre; Provectus; QBiotics; Regeneron
 
Christian U. Blank
Stock and Other Ownership Interests - Immagene
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Third Rock Ventures
Research Funding - 4SC (Inst); Bristol-Myers Squibb (Inst); NanoString Technologies (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - WO 2021/177822 A1
Expert Testimony - Freshfields Bruckhaus Deringer
Travel, Accommodations, Expenses - Bristol-Myers Squibb